Corporate ActionAug 12, 2026, 05:27 PM
Silence Therapeutics Prices $175M Upsized Public Offering of ADSs
AI Summary
Silence Therapeutics plc announced the pricing of its upsized underwritten public offering of 12,962,963 American Depositary Shares (ADSs) at $13.50 per ADS. The offering is expected to generate gross proceeds of approximately $175 million. The company estimates net proceeds of about $164.0 million, or $188.7 million if the underwriters fully exercise their option to purchase an additional 1,944,444 ADSs. The closing of the offering is anticipated on August 13, 2026.
Key Highlights
- Offering priced at $13.50 per American Depositary Share (ADS).
- 12,962,963 ADSs to be issued in the public offering.
- Gross proceeds expected to be approximately $175 million.
- Estimated net proceeds are $164.0 million after deductions.
- Underwriters granted a 30-day option to purchase an additional 1,944,444 ADSs.
- Net proceeds could reach $188.7 million if the option is fully exercised.
- Each ADS represents three ordinary shares of the Company.
Price Impact
More from SLN